Inclusion Criteria:  Patient diagnosed with chronic HF ≥3 months prior to signature of informed consent. Patient has at least 1 record of left ventricular ejection fraction (LVEF) documented in patient medical record in the 24 months prior to signature of informed consent. Patient treated with angiotensin-converting enzyme inhibitors (ACEi) / angiotensin receptor blockers (ARB) / angiotensin receptor-neprilysin inhibitors (ARNi) at enrolment. Patient treated with or a candidate for treatment with mineralcorticoid receptor antagonist (MRA) per a relevant treatment guideline at enrolment.  Patient at increased risk of hyperkalaemia due to one or more of the following:  Current hyperkalaemia (sK+ >5.0 mEq/L) at enrolment Record of documented hyperkalaemia (sK+ >5.0 mEq/l) in the 24 months prior to signature of informed consent estimated glomerular filtration rate (eGFR) <45 mL/min/1.73m2, or Chronic Kidney Disease (CKD) stage ≥3b. Patient judged by the Investigator to have sufficient cognitive ability to participate  Exclusion Criteria:  Patient on renal replacement therapy or mechanical circulatory support. Disease other than HF with expected survival <1 year. Patient is participating in, or being screened for, an interventional trial. Patient already found to be intolerant to MRA for reasons other than hyperkalaemia or renal impairment.